Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I will do the same.
Best time to SHORT JPM.
Looks like fishing for stops. A major news is coming. Hold on.
This remind me CTIC. I missed the CTIC run.
ABK : Nice V shape chart. Will be testing 200 day avg soon. I want this close over the 200 day AVG.
ABK : Nice V shape chart. Will be testing 200 day avg soon. I want this close over the 200 day AVG.
Nice V shape chart. Will be testing 200 day avg soon. I want this close over the 200 day AVG.
I am holding 750K and not letting go any soon
The market is holding down this. At some point, it should fly again. GLTA
WARNING : DO not flip this. If you do, then You will end up chasing it.
CORS : Short will push this over $2.00 very soon
Short Interest (Shares Short) 8,515,100
Days To Cover (Short Interest Ratio) 5.3
Short Percent of Float 19.86 %
Short Interest - Prior 8,463,400
Short % Increase / Decrease 0.61 %
Short Squeeze Ranking™ -97
% From 52-Wk High ($ 10.58 ) -1663.33 %
% From 52-Wk Low ($ 0.09 ) 84.83 %
% From 200-Day MA ($ 0.34 ) 43.33 %
% From 50-Day MA ($ 0.25 ) 58.33 %
Price % Change (52-Week) -92.10 %
Shares Float 42,870,000
Total Shares Outstanding 53,711,680
% Owned by Insiders 26.18 %
% Owned by Institutions 26.30 %
Market Cap. $ 32,227,008
Trading Volume - Today 10,001,964
Trading Volume - Average 1,594,600
Trading Volume - Today vs. Average 627.24 %
Earnings Per Share -13.83
PE Ratio
Record Date 2009-Aug
CORS : Short will push this over $2.00 very soon
Short Interest (Shares Short) 8,515,100
Days To Cover (Short Interest Ratio) 5.3
Short Percent of Float 19.86 %
Short Interest - Prior 8,463,400
Short % Increase / Decrease 0.61 %
Short Squeeze Ranking™ -97
% From 52-Wk High ($ 10.58 ) -1663.33 %
% From 52-Wk Low ($ 0.09 ) 84.83 %
% From 200-Day MA ($ 0.34 ) 43.33 %
% From 50-Day MA ($ 0.25 ) 58.33 %
Price % Change (52-Week) -92.10 %
Shares Float 42,870,000
Total Shares Outstanding 53,711,680
% Owned by Insiders 26.18 %
% Owned by Institutions 26.30 %
Market Cap. $ 32,227,008
Trading Volume - Today 10,001,964
Trading Volume - Average 1,594,600
Trading Volume - Today vs. Average 627.24 %
Earnings Per Share -13.83
PE Ratio
Record Date 2009-Aug
CORS : do not miss the boat.
CORS $$$$$$$$$$$$$$$$$
Looks like it will pass $1.00 today. GLTA
Big blocks start to shows up on the bid. $1.00 shoudl be seen very soon. If the buyout occur, it should be atleast 3-4 range. Hope for the best. GLTA
Barclays Plc Institution
2009-08-13
13F-HR 187,921 Added More
cors : buy buy buy
Barclays Plc Institution
2009-08-13
13F-HR 187,921 Added More
Starwood want to buy CORS
http://online.wsj.com/article/SB124752110843034923.html
Nice profit from GFG. GLTA
GFG : NAZ stock @ pink sheet price
Thanks for the info. I stop trading the OB and PK stocks. Only stick with Naz stocks. GLTY
GFG and CORS WEEEEEEEEEEEEEEEEEEEEEEEE
Take a look at CORS NZ stock
Starwood is hunting for CORS to buy cheap?
http://online.wsj.com/article/SB124752110843034923.html
Starwood is hunting for CORS to buy cheap?
http://online.wsj.com/article/SB124752110843034923.html
7 million difference between the buy and sell volume. I am holding over the weekend.
1.06/1.07 very good support.
I am holding 4K shares bought at 4.14
WHYYYYYYYYYYYYYYYYYYY
Premarket is going crazy.
Clay, could you post the annoted chart for LJPC? TIA
Great News : LaJolla Pharmaceuticals Co. could seek to partner with someone for the sale of Riquent, a potential treatment for the treatment of lupus nephritis currently in Phase III testing, outside of the U.S.
http://www.marketwatch.com/story/more-biotech-partnerships-expected
Great News : LaJolla Pharmaceuticals Co. could seek to partner with someone for the sale of Riquent, a potential treatment for the treatment of lupus nephritis currently in Phase III testing, outside of the U.S.
http://www.marketwatch.com/story/more-biotech-partnerships-expected
LJPC : NEWS
LA JOLLA PHARMACEUTICAL COMPANY (NASDAQ: LJPC) "Up 59.37% in morning trading" La Jolla Pharmaceutical Company is dedicated to improving and preserving human life by developing innovative pharmaceutical products. The Company's leading product in development is Riquent®, which is designed to treat lupus renal disease by preventing or delaying renal flares. Lupus renal disease is a leading cause of sickness and death in patients with lupus. The Company has also developed potential small molecule drug candidates to treat various other autoimmune and inflammatory conditions.
What is the trend on LJPC? It looks god to me. Any openion on the chart? TIA
Where is every one? Exciting day here and next week.
LJPC Hurdle for Merger Cleared 23-Jul-09 11:35 pm
On May 22, 2009, the La Jolla Pharmaceutical Co. and its directors were sued by BioMarin Pharmaceutical Company in California Superior Court, alleging breach of contract, breach of covenant of good faith and fair dealing, and breach of fiduciary duty. BioMarin, which had been the company's development partner for Riquent, sued to force the company to accelerate the timing for the registration of approximately 10 million shares of restricted common stock that BioMarin had purchased from the company when entering into the collaboration for Riquent in January 2009. Additionally, BioMarin seeks to recover damages for any loss it may suffer due to the alleged breach. The Company believes these claims are wholly without merit. Prior to the filing of the BioMarin lawsuit, the company had made significant progress negotiating a potential merger with another company and was working toward the execution of a definitive merger agreement and the announcement of the transaction. However, in light of the pending lawsuit by BioMarin and the expected impact on the ability to complete the Merger, as well as the potential litigation damages and the defense costs, the company's Board of Directors concluded that it is impractical for the company to pursue the merger or other any similar transaction with another party.
LJPC : Take a look at it. GLTA
LJPC LJPC LJPC : Naz stock at penny price. WEEEEEEEEEEEEEEE
This will be multibager from here. The main concerns is cleared. Clean sail from here. Great pipeline. GLTA